Research
Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg/week and liraglutide 3 mg/day) produce significant weight loss in adults with obesity or overweight with comorbidities by delaying gastric emptying and increasing satiety, with semaglutide demonstrating superior efficacy compared to liraglutide.
If you have obesity or overweight with a related health condition, ask your doctor about GLP-1 agonists like semaglutide. They are taken as a once-weekly injection and work by making you feel full and slowing digestion. They are most effective when combined with a reduced-calorie diet and increased physical activity.
GoodSupportsHIGH confidence
subcutaneous injection of 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight... The mean body weight change from baseline was higher with semaglutide as participants had significantly greater odds of achieving 10% or more, 15% or more, and 20% or more weight loss with semaglutide vs. liraglutide
Why this rating
Based on phase 3 clinical trials and FDA approval.
Source
Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges
Skyler Brandfon et al. · Cureus · 2023
DOI 10.7759/cureus.46623
narrative_reviewCited 38×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Leptin analogs (metreleptin) are effective for treating obesity only in patients with generalized lipodystrophy or congenital leptin deficiency, but are ineffective and contraindicated for general diet-based obesity due to leptin resistance.Good
- MC4R agonists (setmelanotide) are effective for treating obesity in individuals with specific genetic deficiencies (POMC, PCSK1, LEPR) or Bardet-Biedl syndrome, but are not approved for general obesity.Good
- Lipase inhibitors (orlistat and cetilistat) reduce weight by inhibiting fat absorption, but are associated with gastrointestinal side effects and are less effective in patients with diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →